Pharma major Lupin’s net profit for the January-March quarter stood at Rs 220 crore — a growth of 40 per cent over the corresponding quarter last year. The company also witnessed a 23 per cent rise in its net sales at Rs 1,285 crore.
For the entire year 2009-10, profits and revenues grew by 36 per cent and 26 per cent respectively over FY 2008-09.
Strong growth in the US and Europe contributed to the company’s gains. In the last quarter, sales in the US, EU and Japan grew 33 per cent and accounted for 55 per cent of revenues.
“We have continued to outperform across business segments and markets; with robust growth in advanced markets, solid domestic growth and increased presence in emerging markets,” said, Lupin MD Kamal K Sharma.